scholarly journals Screening for Olfactory Dysfunction in COVID-19 Patients Using Quick Smell Identification Test

2021 ◽  
Author(s):  
Hussain Abdullali Albaharna ◽  
Alya Hassan Alhajjaj ◽  
Hussain Ali Al Shabeb ◽  
Dhuha Abdulaziz Alghanim ◽  
Fatimah Lateef Alkhabbaz ◽  
...  
Keyword(s):  
Olfactory Dysfunction ◽  
Identification Test ◽  
Smell Identification

scholarly journals Olfactory Dysfunction in Coronavirus Disease 2019 Patients: Observational Cohort Study and Systematic Review

2020 ◽  
Vol 7 (6) ◽  
Author(s):  
Tom Wai-Hin Chung ◽  
Siddharth Sridhar ◽  
Anna Jinxia Zhang ◽  
Kwok-Hung Chan ◽  
Hang-Long Li ◽  
...  
Keyword(s):  
Systematic Review ◽  
Immunohistochemical Analysis ◽  
Observational Cohort Study ◽  
Olfactory Dysfunction ◽  
Threshold Test ◽  
Clinical Recovery ◽  
Identification Test ◽  
Observational Cohort ◽  
Smell Identification ◽  
Nasal Biopsy

Abstract Background Olfactory dysfunction (OD) has been reported in coronavirus disease 2019 (COVID-19). However, there are knowledge gaps about the severity, prevalence, etiology, and duration of OD in COVID-19 patients. Methods Olfactory function was assessed in all participants using questionnaires and the butanol threshold test (BTT). Patients with COVID-19 and abnormal olfaction were further evaluated using the smell identification test (SIT), sinus imaging, and nasoendoscopy. Selected patients received nasal biopsies. Systematic review was performed according to PRISMA guidelines. PubMed items from January 1, 2020 to April 23, 2020 were searched. Studies that reported clinical data on olfactory disturbances in COVID-19 patients were analyzed. Results We included 18 COVID-19 patients and 18 controls. Among COVID-19 patients, 12 of 18 (67%) reported olfactory symptoms and OD was confirmed in 6 patients by BTT and SIT. Olfactory dysfunction was the only symptom in 2 patients. Mean BTT score of patients was worse than controls (P = .004, difference in means = 1.8; 95% confidence interval, 0.6–2.9). Sinusitis and olfactory cleft obstruction were absent in most patients. Immunohistochemical analysis of nasal biopsy revealed the presence of infiltrative CD68+ macrophages harboring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen in the stroma. Olfactory dysfunction persisted in 2 patients despite clinical recovery. Systematic review showed that the prevalence of olfactory disturbances in COVID-19 ranged from 5% to 98%. Most studies did not assess olfaction quantitatively. Conclusions Olfactory dysfunction is common in COVID-19 and may be the only symptom. Coronavirus disease 2019-related OD can be severe and prolonged. Mucosal infiltration by CD68+ macrophages expressing SARS-CoV-2 viral antigen may contribute to COVID-19-related OD.

scholarly journals Screening for Olfactory Dysfunction in COVID-19 Patients Using Quick Smell Identification Test

2020 ◽  
Author(s):  
Hussain Albaharna ◽  
Alya Alhajjaj ◽  
Hussain Al Shabeb ◽  
Dhuha Alghanim ◽  
Fatimah Alkhabbaz ◽  
...  
Keyword(s):  
Olfactory Dysfunction ◽  
Identification Test ◽  
Smell Identification

Smoking-Induced Olfactory Dysfunction in Chronic Sinusitis and Assessment of Brief University of Pennsylvania Smell Identification Test and T&T Methods

2006 ◽  
Vol 20 (5) ◽  
pp. 439-444 ◽  
Author(s):  
Kazuko Sugiyama ◽  
Yasuhiro Hasegawa ◽  
Naruji Sugiyama ◽  
Motohiko Suzuki ◽  
Nobuhiro Watanabe ◽  
...  
Keyword(s):  
Chronic Sinusitis ◽  
Olfactory Dysfunction ◽  
University Of Pennsylvania ◽  
Identification Test ◽  
Smell Identification

scholarly journals Letter to the editor: Study Summary - Randomized Control Trial of Omega-3 Fatty Acid Supplementation for the Treatment of COVID-19 Related Olfactory Dysfunction

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
David Lerner ◽  
Katherine Garvey ◽  
Annie Arrighi-Allisan ◽  
Andrey Filimonov ◽  
Peter Filip ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Olfactory Dysfunction ◽  
Omega 3 ◽  
Fatty Acid Supplementation ◽  
Acid Supplementation ◽  
Omega 3 Fatty Acid ◽  
Identification Test ◽  
History Of ◽  
Full Protocol ◽  
Smell Identification

Abstract Objectives To evaluate a therapeutic role for omega-3 fatty acid supplementation in the treatment of olfactory dysfunction associated with COVID-19 infection Trial design Randomized, double-blinded, placebo-controlled trial Participants Eligible patients are adults with self-reported new-onset olfactory dysfunction of any duration associated with laboratory-confirmed or clinically suspected COVID-19 patients. Exclusion criteria include patients with pre-existing olfactory dysfunction, history of chronic rhinosinusitis or history of sinus surgery, current use of nasal steroid sprays or omega-3 supplementation, fish allergy, or inability to provide informed consent for any reason. The trial is conducted at Mount Sinai Hospital Intervention and comparator The intervention group will receive 2000 mg daily of omega-3 supplementation in the form of two “Fish Oil, Ultra Omega-3” capsules (product of Pharmavite®) daily. The comparator group will take 2 placebo capsules of identical size, shape, and odor daily for 6 weeks. Main outcomes Each subject will take a Brief Smell Identification Test at study enrolment and completion after 6 weeks. The primary outcome will be change in Brief Smell Identification Test over the 6-week period. Randomisation Patients will be randomized by the Investigational Drug Pharmacy at the Icahn School of Medicine at Sinai via a computer-generated sequence in a 1:1 allocation to treatment or control arms. Blinding (masking) Both participants and researchers will be blinded. Numbers to be randomised (sample size) There will be 88 participants randomized to each group. A total of 176 participants will be randomized. Trial Status Protocol Version 1, 8/3/2020 Recruitment is ongoing, started 8/5/2020 with estimated completion 11/30/2020. Trial registration The trial is registered on ClinicalTrials.gov with Protocol Identifier: NCT04495816. Trial registration: ClinicalTrials.gov, NCT04495816. Registered 3 August 2020 Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).

scholarly journals 4347 Bimodal Visual-Olfactory Training for Post-Surgical or Post-Traumatic Olfactory Dysfunction (VOLT Trial)

2020 ◽  
Vol 4 (s1) ◽  
pp. 23-24
Author(s):  
Andrew Michael Peterson ◽  
Dorina Kallogjeri ◽  
Jay Piccirillo
Keyword(s):  
Quality Of Life ◽  
Olfactory Dysfunction ◽  
Olfactory Function ◽  
Quality Of Life Questionnaires ◽  
Patient Reported ◽  
Identification Test ◽  
Post Traumatic ◽  
Smell Identification ◽  
Olfactory Training

OBJECTIVES/GOALS: 1) Assess the patient-reported, perceived change in olfactory function after bimodal visual-olfactory training (OT) 2) Assess change in olfactory function after bimodal visual-olfactory training with a smell identification test 3) Assess which scents are most important to people with olfactory dysfunction (OD) METHODS/STUDY POPULATION: The participants are adults with subjective or clinically diagnosed OD with post-surgical or traumatic etiologies within the last 5 years. At the first of two study visits, participants complete the University of Pennsylvania Smell Identification Test (UPSIT) and complete general health (SF-36) and olfactory-related quality-of-life questionnaires. From a list of 34 scents, participants chose the 4 scents most important to them and smelled the scents twice daily for 3 months. Olfactory testing and the quality-of-life questionnaires were repeated at the final visit. RESULTS/ANTICIPATED RESULTS: 10 participants have enrolled in the study. There was one screen fail and one withdrawal. Six participants are currently undergoing OT and two have completed the study. Seven participants have post-surgical etiology and three have post-traumatic etiology of their OD. Of the two participants who have completed the study, one had an UPSIT score improvement from 25 to 33 out of the 40 questions correct. The minimally clinically important difference on the UPSIT is 4. She reports improvement subjectively. The second participant had a UPSIT score change from 25 to 24 and reports ability to smell is neither better nor worse. DISCUSSION/SIGNIFICANCE OF IMPACT: Traumatic and post-surgical, particularly post-transphenoidal hypophysectomy, are common etiologies of OD and no effective treatments exist. The results from our pilot study will help better inform the best way to undergo OT, how effective it is, and the planning of future studies.

scholarly journals Low specificity and sensitivity of smell identification testing for the diagnosis of Parkinson?s disease

2014 ◽  
Vol 72 (1) ◽  
pp. 33-37 ◽  
Author(s):  
Mayela Rodríguez-Violante ◽  
Paulina Gonzalez-Latapi ◽  
Azyadeh Camacho-Ordoñez ◽  
Daniel Martínez-Ramírez ◽  
Hugo Morales-Briceño ◽  
...  
Keyword(s):  
Diagnostic Tool ◽  
Olfactory Dysfunction ◽  
Cross Cultural ◽  
Healthy Controls ◽  
Control Subjects ◽  
Specificity And Sensitivity ◽  
Identification Test ◽  
The Mean ◽  
The University ◽  
Smell Identification

Objective: The aim of this study is to determine if the University of Pennsylvania’s Smell Identification Test (UPSIT) is an accurate diagnostic tool for olfactory dysfunction in Parkinson’s disease (PD). Method: We included 138 non-demented PD subjects and 175 control subjects matched by gender. Smell identification was tested using UPSIT. Results: The mean number of UPSIT items correctly identified by controls was 27.52±5.88; the mean score for PD subjects was 19.66±6.08 (p=<0.001). UPSIT sensitivity was 79.7% with a specificity of 68.5% using a cut-off score of ≤25. The overall accuracy for the diagnosis of PD was of 75.3%. Conclusion: UPSIT accuracy and specificity were lower than what has been previously reported. Our data demonstrates that 17.5% of items of the UPSIT were not well identified by healthy controls. Further research of the identification of a truly cross-cultural test is warranted.

scholarly journals Prevalence of olfactory dysfunction in COVID-19 patients

2021 ◽  
Author(s):  
Mohammad Bayat ◽  
Amirmohammad Arabi ◽  
Amirali Assadi ◽  
Saina Nezami Nia ◽  
Masoud Mortezazadeh ◽  
...  
Keyword(s):  
Normal Population ◽  
Olfactory Dysfunction ◽  
Olfactory Function ◽  
University Of Pennsylvania ◽  
Infected People ◽  
Screening Programs ◽  
Identification Test ◽  
Back Ground ◽  
The University ◽  
Smell Identification

Back ground: Nowadays COVID-19 has become a pandemic in which global society experience multiple difficulties in management. It seems that olfactory dysfunction is one of the early occurring symptoms of this viral infection and many patients just show this symptom after they got infected. Considering so, olfactory dysfunction especially a decline in olfaction could potentially be used for screening purposes and preventing the disease to spread. Methods: 50 PCR-verified SARS-CoV-2 infected participants were assessed about their olfactory function adequacy using a Modified Version of the University of Pennsylvania Smell Identification Test (UPSIT) for the Iranian population called Iran Smell Identification Test (Iran-SIT). Participants scores were compared against normal population scores in this test and possible correlations of age and scores were explored as well Results: Participants with SARS-CoV-2 infection generally obtained lesser scores in the mentioned test which means they experience a decline in olfactory function more, significantly. Aging also has a negative correlation with olfaction adequacy. Conclusion: Based on this article’s finding, olfactory function decrease is more frequent among SARS-CoV-2 infected people and potentially could be a suggestive indicator for screening programs. This indicator should be interpreted concerning patients’ age.

Sign in / Sign up

Export Citation Format

Share Document